Northwestern Mutual Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-10
Closed -$11 – 3818
2025
Q2
$11 Hold
10
– – ﹤0.01% 3626
2025
Q1
$13 Hold
10
– – ﹤0.01% 3616
2024
Q4
$23 Sell
10
-1
-9% -$2 ﹤0.01% 3540
2024
Q3
$37 Hold
11
– – ﹤0.01% 3531
2024
Q2
$55 Buy
+11
New +$82 ﹤0.01% 3418

Other funds holding BCLI

Northwestern Mutual Wealth Management's BCLI Position: Q3 2025 in Review

Northwestern Mutual Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 10 shares — an estimated $11 sold.

Northwestern Mutual Wealth Management first reported a position in BCLI in Q2 2024 and held it in 5 quarters. The position peaked at $55 in Q2 2024. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Northwestern Mutual Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 10 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $11.
  • Northwestern Mutual Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2024 and held it in 5 quarters.
  • Northwestern Mutual Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $55 in Q2 2024.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Northwestern Mutual Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.